Aardvark Therapeutics (NASDAQ:AARD) Announces Quarterly Earnings Results

Posted by on Aug 11th, 2026

Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21, Zacks reports.

Aardvark Therapeutics Price Performance

Shares of NASDAQ AARD traded down $0.37 during midday trading on Tuesday, reaching $7.19. The company’s stock had a trading volume of 177,813 shares, compared to its average volume of 256,011. The stock has a market capitalization of $157.32 million, a P/E ratio of -2.24 and a beta of 3.80. The firm has a 50 day moving average price of $5.42 and a 200-day moving average price of $6.67. Aardvark Therapeutics has a 12-month low of $3.35 and a 12-month high of $17.94.

Institutional Trading of Aardvark Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC boosted its position in Aardvark Therapeutics by 5.9% in the third quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock worth $18,073,000 after purchasing an additional 76,151 shares during the last quarter. Laurion Capital Management LP increased its position in shares of Aardvark Therapeutics by 6.1% during the 3rd quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock valued at $13,951,000 after purchasing an additional 60,653 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Aardvark Therapeutics by 20.6% during the 3rd quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock worth $7,386,000 after purchasing an additional 94,744 shares during the period. Millennium Management LLC raised its stake in shares of Aardvark Therapeutics by 51.2% during the 4th quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock worth $6,344,000 after purchasing an additional 163,717 shares during the period. Finally, SymBiosis Capital Partners LLC purchased a new position in shares of Aardvark Therapeutics in the 4th quarter worth about $6,255,000.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. BTIG Research downgraded shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. B. Riley Financial dropped their price target on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. HC Wainwright reiterated a “neutral” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research note on Monday, July 20th. Morgan Stanley reissued an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. Finally, Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $16.30.

Check Out Our Latest Stock Analysis on AARD

Aardvark Therapeutics Company Profile

(Get Free Report)

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.

Featured Stories

Earnings History for Aardvark Therapeutics (NASDAQ:AARD)

Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.